Demands for vaccines continues to increase as the world's population grows and changes. To meet this demand, GSK must deliver reliable, high quality vaccines and push the boundaries of science and technology to develop innovative vaccines.
Synflorix is a Pneumococcal polysaccharide conjugate vaccine. Indicated for Active immunization against invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F and cross-reactivate serotype 19A in infants , and children from 6 weeks up to 5 years of age.
Rotarix is a live attenuated rotavirus vaccine Rotarix is indicated for the prevention of gastro-enteritis caused by rotavirus.
Havrix (720 Junior)
Havrix Adult is indicated for active immunization against hepatitis A virus (HAV) infection in subjects at risk of exposure to HAV, for Children and adolescents from 1 year up to and including 18 years of age.
Varilrix is indicated for active immunization against varicella of healthy subjects from the age of 12 months onwards.
Twinrix Adult is indicated for use in non-immune adults and adolescents of 16 years of age and above who are at risk of both hepatitis A and hepatitis B infection.
Havrix (1440 Adult)
Havrix Adult is indicated for active immunization against hepatitis A virus (HAV) infection in subjects at risk of exposure to HAV, from age 19 years and onwards.
Priorix is indicated for the active immunization against measles, mumps and rubella.
Hiberix is indicated for active immunization of all infants from the age of 6 weeks against disease caused by Haemophilus influenzae type b.
Cervarix is indicated from the age of 9 years for the prevention of persistent infection, premalignant ano-genital lesions (cervical, vulvar, vaginal and anal) and cervical, vulvar, vaginal and anal cancers (squamous-cell carcinoma and adenocarcinoma) caused by oncogenic Human Papillomaviruses (HPV).